Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model
- 1 July 2002
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (7) , 897-905
- https://doi.org/10.1211/002235702760089009
Abstract
The objectives of this study were to characterize the pharmacokinetics of vascular endothelial growth factor (VEGF) in poly(lactic-co-glycolic) acid (PLGA) microspheres using a rat model, and to develop a pharmacokinetic model for this controlled release formulation. 14C-VEGF was encapsulated using a solid-in-oil-in-water emulsification method. The microspheres were administered subcutaneously to rats and the pharmacokinetic parameters were compared with those of protein solutions. Intravenous administration of protein solutions resulted in short half-lives and subcutaneous administration resulted in rapid clearance from the subcutaneous tissue, with high plasma concentrations as expressed by rapid absorption and elimination. The subcutaneous administration of the VEGF microspheres produced low plasma concentrations and high subcutaneous concentrations over a period of 7 weeks. The area under the curve (AUC), the time required to achieve the maximum concentration (tmax), the maximum concentration (Cmax) in blood samples and the elimination rate constant (kel) values at the subcutaneous tissue site were selected to compare the pharmacokinetic characterization of VEGF microspheres with that of protein solutions. The in-vivo release profiles of the proteins were slower than the in-vitro release profiles and they followed the same trend as the in-vitro and in-vivo PLGA degradation rates. The PLGA microsphere degradation was the determinant step for VEGF release from the microspheres and its absorption at the subcutaneous site. Microspheres appear to be an attractive system for the localized rate-controlled delivery of VEGF. 14C-Methylation via reductive alkylation of VEGF did not affect its mitogenic activity, however approximately 25% activity was lost following release from PLGA microspheres. This loss of activity may be due to degradation in an acidic environment as a result of PLGA degradation.Keywords
This publication has 17 references indexed in Scilit:
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- Formulation and release characteristics of poly(lactic-co-glycolic acid) microspheres containing chemically modified proteinJournal of Pharmacy and Pharmacology, 2001
- Controlled release of therapeutic agents: slow delivery and cell encapsulation.World Journal of Urology, 2000
- Structure−Property Model for Membrane Partitioning of OligopeptidesJournal of Medicinal Chemistry, 1999
- Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: Release kinetics and stability issuesJournal of Microencapsulation, 1998
- The Stability of Recombinant Human Growth Hormone in Poly(lactic-co-glycolic acid) (PLGA) MicrospheresPharmaceutical Research, 1997
- Crystallization of the receptor binding domain of vascular endothelial growth factorProteins-Structure Function and Bioinformatics, 1996
- The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic PotencyJournal of Biological Chemistry, 1996
- Reductive Alkylation of ProteinsAnalytical Biochemistry, 1995
- Potential use of albumin microspheres as a drug delivery systemInternational Journal of Pharmaceutics, 1988